CovX
This article was originally published in Start Up
Executive Summary
It's rare to find a drug development start-up that has grown to more than 50 people and raised over $100 million before putting its first molecule into the clinic. That's the history of CovX, which uses a humanized antibody as a scaffold for developing multiple drugs with the desirable properties of both the antibody and specific peptides or small molecules that are linked to it.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.